Shares of the Ahmedabad-based biopharma company, which listed a few weeks ago at a more than 20% premium, have notched another 9% gain since then. The shares topped ₹1,000 in intraday trade on Friday, before closing nearly 2% higher on the NSE at ₹983.40.
Concord Biotech’s niche strengths seen buoying earnings: Analysts
Date:
More like thisRelated
From My ‘Commonplace Book,’ No. 9: Thomas Mann, Richard Wagner, and Adolf Hitler
There's nothing like a look back at Germany in...
6 Trump Inauguration speech highlights — and how the internet reacted
Trump promises that a 'golden age of America begins...
Trump’s ‘External Revenue Service’ Is a Public Relations Effort. It Won’t Change How Tariffs Work.
Trump promises to "tariff and tax foreign countries to...